Generic Invokana ( Canagliflozin )

Order cheap Generic Invokana (Canagliflozin) without dr prescription in the United States

In our USA pharmacy, you can buy Invokana without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Invokana (canagliflozin) is a sodium‑glucose cotransporter 2 (SGLT2) inhibitor used to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events and kidney function decline in adults with type 2 diabetes and established cardiovascular disease or diabetic kidney disease. It works by blocking the reabsorption of glucose in the kidneys, causing excess sugar to be excreted in the urine.
Usual adult dose: The recommended starting dose is 100 mg taken orally once daily before the first meal of the day. The dose can be increased to 300 mg once daily in patients with normal kidney function (eGFR ≥60 mL/min/1.73 m²) who tolerate the 100 mg dose and need additional glycemic control. For patients with moderate renal impairment (eGFR 30 to Dosage form: Oral tablet (100 mg and 300 mg).
Onset of action: Increased urinary glucose excretion begins within hours of the first dose; a meaningful reduction in fasting blood sugar can be observed within 1‑2 weeks, with maximal glucose‑lowering effect typically achieved after 4‑8 weeks.
Duration of action: A single daily dose provides 24‑hour inhibition of SGLT2, allowing once‑daily dosing.
Alcohol consumption should be moderate; heavy alcohol intake may increase the risk of diabetic ketoacidosis, particularly in the setting of fasting, malnutrition, or intercurrent illness, and may worsen dehydration.
Most common side effects: genital yeast infections (in women and men), urinary tract infections, increased urination, increased thirst, constipation, and nausea.
Would you like to try Invokana without a prescription?

General Information about Invokana

• INN (International Nonproprietary Name): Canagliflozin
• Brand names available in the USA: Invokana® (Janssen Pharmaceuticals, Inc., a Johnson & Johnson company). Generic canagliflozin tablets are manufactured by several companies including Teva Pharmaceuticals USA, Inc., Aurobindo Pharma USA, Inc., and others.
• ATC code: A10BK02
• Dosage forms and strengths: Film‑coated oral tablets containing 100 mg or 300 mg of canagliflozin.
• Manufacturers in USA: Janssen Pharmaceuticals, Inc. (brand Invokana®); generic manufacturers include Teva Pharmaceuticals USA, Inc., Aurobindo Pharma USA, Inc., and other FDA‑approved companies.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) on March 29, 2013 (NDA 204042).
• OTC / Rx classification: Prescription only (Rx).

Mechanism of Action and Pharmacology

Canagliflozin is a reversible, competitive inhibitor of the sodium‑glucose cotransporter 2 (SGLT2), a transporter located in the proximal renal tubule responsible for the majority of filtered glucose reabsorption. By inhibiting SGLT2, canagliflozin reduces the renal threshold for glucose, leading to increased urinary glucose excretion and a net caloric loss. This mechanism lowers blood glucose independently of insulin action and secretion, thereby reducing fasting and postprandial hyperglycemia. Canagliflozin also has mild SGLT1 inhibitory activity, which may contribute to a modest reduction in intestinal glucose absorption. The osmotic diuresis resulting from glycosuria also lowers blood pressure and reduces body weight. After oral administration, canagliflozin is rapidly absorbed; peak plasma concentrations occur within 1‑2 hours. Taking the tablet with a high‑fat meal slightly delays the time to peak concentration but does not meaningfully alter overall exposure. The drug is extensively metabolized via O‑glucuronidation, primarily by UGT1A9 and UGT2B4, and is then excreted in urine and feces. The elimination half‑life is approximately 11‑13 hours, which supports once‑daily dosing.

Indications

• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• To reduce the risk of major adverse cardiovascular events (cardiovascular death, non‑fatal myocardial infarction, and non‑fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
• To reduce the risk of end‑stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria.

Important Warnings and Precautions

Invokana carries a boxed warning for lower limb amputation, based on an approximately two‑fold increased risk of toe and mid‑foot amputations observed in a large cardiovascular outcomes trial (CANVAS). The risk appears to be greater in patients with a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers. Before initiating canagliflozin, a thorough foot examination should be performed, and patients must be counseled on daily foot care and on reporting any new pain, tenderness, sores, or ulcers. The drug should be discontinued if a significant foot complication develops. Additionally, SGLT2 inhibitors including canagliflozin are associated with euglycemic diabetic ketoacidosis (DKA), which may present with normal or only modestly elevated blood glucose levels, potentially delaying recognition. Risk factors include acute illness, reduced caloric or fluid intake, surgery, alcohol abuse, and pancreatic disorders. Patients should be instructed to seek immediate medical attention if symptoms of ketoacidosis — nausea, vomiting, abdominal pain, malaise, and shortness of breath — occur, even if blood sugar is not high. Other important warnings include acute kidney injury, volume depletion leading to hypotension, hyperkalemia, serious urinary tract infections including urosepsis and pyelonephritis, and necrotizing fasciitis of the perineum (Fournier's gangrene). Genital mycotic infections are very common and may require topical or oral antifungal therapy. Hypoglycemia can occur when combined with insulin or insulin secretagogues; a lower dose of the concomitant agent may be needed. Bone fractures have been reported with canagliflozin, with increased risk noted as early as 12 weeks after initiation. Routine monitoring of renal function, potassium, and foot health is essential throughout therapy.

At‑risk groups

• Elderly: No specific dose adjustment based solely on age, but older adults are more likely to have renal impairment, volume depletion, or peripheral vascular disease, which increase the risk of adverse events. Lower initial doses and careful monitoring are advised.
• Pregnancy: Use is not recommended during the second and third trimesters; SGLT2 inhibitors may cause fetal renal toxicity. Use during pregnancy only if the potential benefit justifies the potential risk. If pregnancy is detected, discontinue canagliflozin.
• Breastfeeding: It is not known whether canagliflozin is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment.
• Renal impairment: For glycemic control, canagliflozin is not recommended when eGFR is below 45 mL/min/1.73 m². For patients with moderate renal impairment (eGFR 30 to
• Hepatic impairment: No dose adjustment is required for mild to moderate hepatic impairment. Canagliflozin has not been studied in severe hepatic impairment; use is not recommended.
• Pediatric: Safety and effectiveness have not been established in patients under 18 years of age.
• Amputation risk: Before initiating therapy, consider factors that may increase the risk of amputation, such as prior amputation, peripheral vascular disease, neuropathy, and foot ulcers. Counsel patients on preventive foot care.

Driving and alcohol

Invokana is not known to impair the ability to drive or operate machinery. However, patients taking canagliflozin in combination with insulin or insulin secretagogues may experience hypoglycemia, which can affect concentration and reaction time; blood glucose should be checked before driving. Alcohol consumption should be moderate. Heavy alcohol intake, especially in the setting of fasting or poor nutrition, can predispose patients to euglycemic diabetic ketoacidosis. Additionally, alcohol may increase the risk of dehydration when combined with the diuretic effect of canagliflozin.

Dosage Instructions

• Glycemic control: The recommended starting dose is 100 mg orally once daily, taken before the first meal of the day. In patients with normal renal function (eGFR ≥60 mL/min/1.73 m²) who tolerate the 100 mg dose and require additional glycemic control, the dose may be increased to 300 mg once daily.
• Renal or cardiovascular protection (diabetic kidney disease): The recommended dose is 100 mg once daily. If the eGFR is ≥60 mL/min/1.73 m² and additional renal protection is desired, the dose may be increased to 300 mg once daily.
• Moderate renal impairment (eGFR 30 to: The dose is limited to 100 mg once daily; the 300 mg dose is not recommended. Canagliflozin should not be initiated for glycemic control when eGFR is
• Administration: Take before the first meal of the day. Swallow the tablet whole with a full glass of water; do not crush, chew, or split.
• Missed dose: If a dose is missed, take it as soon as remembered, but skip the missed dose if it is almost time for the next scheduled dose. Do not take two doses at the same time.
• Volume depletion: Correct any volume depletion or electrolyte imbalances before initiating therapy, especially in elderly patients or those receiving diuretics.

Side Effects and Contraindications

Most common adverse reactions (incidence ≥5%): Female genital mycotic infections (vulvovaginal candidiasis, 10‑15%), urinary tract infections (5‑7%), increased urination (polyuria, 3‑5%), male genital mycotic infections (balanitis, 4‑8%), thirst (polydipsia), constipation, nausea, and fatigue.
Serious adverse reactions: Lower limb amputation (primarily of the toe and mid‑foot; incidence 6.3 vs. 3.4 per 1000 patient‑years in CANVAS), euglycemic diabetic ketoacidosis, acute kidney injury, volume depletion and hypotension, hyperkalemia, serious urinary tract infections including urosepsis and pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), and bone fractures.
Absolute contraindications: Severe renal impairment (eGFR

Drug Interactions

• UGT enzyme inducers (e.g., rifampin, phenytoin, phenobarbital, carbamazepine): May significantly reduce canagliflozin exposure, potentially decreasing efficacy. If co‑administration with a UGT inducer is necessary, consider increasing the canagliflozin dose to 300 mg once daily in patients with eGFR ≥60 mL/min/1.73 m² who are already on 100 mg and tolerating it well.
• Digoxin: Canagliflozin may increase digoxin exposure by approximately 20%. Monitor digoxin levels or clinical response if used together.
• Insulin and insulin secretagogues (sulfonylureas, meglitinides): Increased risk of hypoglycemia; a lower dose of the concomitant agent may be required. Caution is advised.
• Diuretics: Additive volume‑depleting effects; more frequent monitoring of volume status and electrolytes is warranted, especially in the elderly.
• Lithium: Canagliflozin may decrease serum lithium levels; monitor lithium concentrations.
• Alcohol: Excessive alcohol intake can increase the risk of ketoacidosis; moderate intake is recommended.

Practical Advice

• Take Invokana exactly as prescribed, before the first meal of the day. Consistency in timing helps maintain the desired effect.
• Drink adequate fluids throughout the day to prevent dehydration, especially in hot weather or during exercise, as the medication increases urine output.
• Women should be alert for symptoms of vaginal yeast infection (itching, discharge) and men for redness or itching of the penis; these are common but treatable. Inform your healthcare provider if these symptoms occur.
• Examine your feet daily for any new sores, cuts, discoloration, or pain. Report any foot problems immediately, even if they seem minor. Wear comfortable, well‑fitting shoes and never go barefoot.
• Know the warning signs of diabetic ketoacidosis: nausea, vomiting, stomach pain, fatigue, trouble breathing, and a sweet or fruity odor on the breath. Seek emergency medical attention if these develop, even if your blood sugar is not high.
• If you miss a dose, take it as soon as you remember unless it is nearly time for the next one. Do not double dose.
• Periodic blood tests to monitor kidney function and potassium levels are necessary; keep all laboratory appointments.
• If you are scheduled for surgery, inform your surgeon that you are taking Invokana; the medication may need to be temporarily stopped to reduce the risk of ketoacidosis.
• Store at room temperature (20‑25°C / 68‑77°F) in a dry place, away from moisture and heat. Keep the container tightly closed and out of reach of children.
• Never share this medication with anyone else; it is prescribed specifically for your condition.

Alternative Medications

• Other SGLT2 inhibitors: Dapagliflozin (Farxiga), empagliflozin (Jardiance), and ertugliflozin (Steglatro). All share similar glucose‑lowering and cardiovascular/renal benefits but have slightly different side‑effect and dosing profiles.
• GLP‑1 receptor agonists: Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity). Injectable medications that also improve glycemic control, promote weight loss, and reduce cardiovascular events.
• Metformin: The first‑line oral therapy for type 2 diabetes; does not cause weight gain or hypoglycemia and is often used in combination with canagliflozin.
• DPP‑4 inhibitors: Sitagliptin (Januvia), linagliptin (Tradjenta). Oral agents with a neutral effect on weight and a low risk of hypoglycemia, but without the cardiovascular/renal protective data of SGLT2 inhibitors.
• Pioglitazone (Actos): An insulin sensitizer that can be used as an alternative when SGLT2 inhibitors are not tolerated.

Clinical Efficacy

The efficacy of canagliflozin was established in the CANVAS and CREDENCE clinical trial programs. In glycemic control trials, canagliflozin 100 mg reduced HbA1c by approximately 0.8% and 300 mg by about 1.0% compared with placebo, with beneficial reductions in body weight (2‑3 kg) and systolic blood pressure (3‑5 mmHg). The CANVAS cardiovascular outcomes trial demonstrated a 14% reduction in the composite endpoint of cardiovascular death, non‑fatal myocardial infarction, or non‑fatal stroke in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors, although it also identified the increased amputation risk. The CREDENCE trial, which enrolled patients with diabetic nephropathy and albuminuria, showed that canagliflozin 100 mg reduced the risk of the primary composite endpoint (end‑stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death) by 30%, with a consistent safety profile. Based on these data, canagliflozin is recommended by the American Diabetes Association and other guidelines as a second‑line therapy after metformin, particularly for patients with cardiovascular disease, heart failure, or chronic kidney disease.

Important:

Invokana (canagliflozin) is a prescription medication that must be used under the supervision of a healthcare provider experienced in the management of type 2 diabetes. It carries a boxed warning for an increased risk of lower limb amputation; a thorough foot examination is required before starting therapy, and patients must be educated on daily foot care and the need to immediately report any foot sores or pain. Euglycemic diabetic ketoacidosis can occur even with normal blood sugar levels; seek emergency medical help for nausea, vomiting, abdominal pain, or confusion. This drug should be discontinued temporarily before major surgery or during acute illness. Do not use if you have severe kidney impairment (eGFR

How to buy Generic Invokana no prescription U.S. Online Pharmacy